Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors

Table 8 Second-line treatment in patients with unresectable metastatic well-differentiated pancreatic neuroendocrine tumors

Rate the appropriateness of increasing the dose or frequency of octreotide lar beyond 30 mg every 4 wk		Every 4 wk				Every 3 wk					Every 2 wk
In a patient whose primary problem is:		40 mg	60 mg	90 mg	120 mg	30 mg	40 mg	60 mg	90 mg	120 mg	30 mg	40 mg	60 mg	90 mg	120 mg
Uncontrolled secretory symptoms	Who previously responded to a lower dose or frequency	9.03 (0.7)	7.03 (0.7)	1.01 (0.5)	1.01 (0.3)	8.03 (0.8)	7.03 (0.6)	5.52 (1.5)	1.01 (0.6)	1.01 (0.4)	5.02 (2.0)	4.52 (2.2)	3.01 (1.9)	1.01 (0.1)	1.01 (0.1)
Uncontrolled tumor-related symptoms		6.02 (1.7)	5.02 (1.8)	1.01 (0.4)	1.01 (0.3)	5.52 (2.0)	4.52 (1.9)	3.52 (1.8)	1.01 (0.5)	1.01 (0.4)	1.01 (1.5)	1.01 (1.4)	1.01 (0.6)	1.01 (0.1)	1.01 (0.1)
Radiographic progression		5.02 (1.1)	4.52 (1.6)	1.01 (0.3)	1.01 (0.3)	5.04 (2.2)	4.02 (1.9)	2.51 (1.8)	1.01 (0.5)	1.01 (0.5)	1.01 (1.7)	1.01 (1.6)	1.01 (0.5)	1.01 (0.1)	1.01 (0.1)
Uncontrolled secretory symptoms	Who previously did not respond to a lower dose or frequency	7.03 (0.9)	7.03 (0.9)	1.01 (0.5)	1.01 (0.3)	6.02 (1.1)	6.02 (0.9)	3.52 (1.6)	1.01 (0.4)	1.01 (0.5)	3.01 (2.0)	2.51 (1.6)	2.01 (0.8)	1.01 (0.1)	1.01 (0.1)
Uncontrolled tumor-related symptoms		3.52 (1.4)	3.01 (1.5)	1.01 (0.3)	1.01 (0.2)	2.51 (1.0)	3.01 (1.0)	1.51 (0.5)	1.01 (0.2)	1.01 (0.2)	1.01 (0.7)	1.01 (0.4)	1.01 (0.3)	1.01 (0.1)	1.01 (0.1)
Radiographic progression		3.01 (1.4)	3.01 (1.5)	1.01 (0.2)	1.01 (0.2)	2.01 (0.7)	2.51 (1.1)	1.01 (0.6)	1.01 (0.3)	1.01 (0.3)	1.01 (0.6)	1.01 (0.4)	1.01 (0.2)	1.01 (0.1)	1.01 (0.1)

The medians of ratings represents the type of panel consensus that was reached for the particular patient scenario (cell):

¹Median rating 1-3 and no disagreement⁴ = “inappropriate”;

²Median rating 4-6 and no disagreement⁴ = “uncertain”; and

³Median rating 7-9 and no disagreement⁴ = “appropriate”; ⁴ > 2 responses in the range 1-3 and > 2 responses in the range 7-9 = “disagreement”.